Much progress has been made in targeting CD47 for cancer immunotherapy in solid tumors
(ST) and hematological malignancies. We summarized the CD47-related clinical research …

Simple Summary The tumor immune escape mechanisms are key factors in cancer
progression and metastasis. They are an undeniable hurdle for successful cancer treatment …

PD-1 signaling on T cells is the major pathway that limits T cell immunity, but the efficacy of
anti–PD-1 therapy has been limited to a small proportion of patients with advanced cancers …

Solid tumours display a limited response to immunotherapies. By contrast, haematological
malignancies exhibit significantly higher response rates to immunotherapies as compared …

Although targeting the tumor metabolism is performed in cooperation with immunotherapy in
the era of precision oncology, ignorance of immune cells' metabolism has resulted in …

Hypoxia is a known feature of solid tumors and a critical promoter of tumor hallmarks.
Hypoxia influences tumor immunity in a way favoring immune evasion and resistance …

Mutations in STK11/LKB1 in non-small cell lung cancer (NSCLC) are associated with poor
patient responses to immune checkpoint blockade (ICB), and introduction of a Stk11/Lkb1 …

Immunotherapies like the adoptive transfer of gene-engineered T cells and immune
checkpoint inhibitors are novel therapeutic modalities for advanced cancers. However, some …

In the tumor microenvironment (TME), tumor-associated macrophages (TAMs) are the most
abundant immune cells, which act as a key regulator in tumorigenesis and progression …

A novel recombinant SIRPα-Fc fusion protein, IMM01, was constructed and produced using
an in-house developed CHO-K1 cell expression system, and the anti-tumor mechanism of …